Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3534427 | 0.80 | TSHR (0.55) | HRH3L3MBTL1KCNH2 | |
| SCHEMBL3533637 | 0.76 | HRH3 (0.52) | HRH3ALDH1A1 | |
| SCHEMBL3534207 | 0.76 | HRH3 (0.67) | HRH3MEN1KMT2APOLBMAPT | |
| SCHEMBL3531745 | 0.74 | HRH3 (0.53) | HRH3POLBMAPTALDH1A1HRH1 | |
| SCHEMBL3535387 | 0.73 | HRH3 (0.80) | HRH3MEN1KMT2AMAPTKDM4E | |
| SCHEMBL3533815 | 0.71 | HRH3 (0.61) | HRH3MEN1KMT2APOLBMAPT | |
| SCHEMBL14287709 | 0.70 | MEN1 (0.76) | HRH3MEN1KMT2APOLBMAPT | |
| SCHEMBL3531619 | 0.69 | HRH3 (0.77) | HRH3MEN1KMT2AL3MBTL1KDM4E | |
| SCHEMBL3531874 | 0.69 | HRH3 (0.78) | HRH3POLBMAPTKDM4EALDH1A1 | |
| SCHEMBL3534462 | 0.69 | HRH3 (1.00) | HRH3MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1747203-A4 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-22 | — | — | EP | claimed |
| US-7507756-B2 | Scalable synthesis of imidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-24 | — | — | US | claimed |
| EP-1747203-A1 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-31 | — | — | EP | claimed |
| WO-2005110998-A1 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | WO | claimed |
| US-20050250948-A1 | Scalable synthesis of imidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-10 | — | — | US | claimed |
| US-7807837-B2 | Scalable synthesis of imidazole derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-05 | — | — | US | disclosed |
| US-20090143591-A1 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-04 | — | — | US | disclosed |
| US-7507756-B2 | Scalable synthesis of imidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-24 | — | — | US | disclosed |
| EP-1373218-B9 | IMIDAZOLYL DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS | ORTHO MCNEIL JANSSEN PHARM (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1373218-B1 | IMIDAZOLYL DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARM INC (US) | 2008-01-09 | — | — | EP | disclosed |
| US-7265135-B2 | 2-oxy, 2-amino, and 2-thio-imidazole compounds | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20050250948-A1 | Scalable synthesis of imidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-10 | — | — | US | disclosed |
| US-20040147577-A1 | Heterocyclic compounds | BOGENSTAETTER MICHAEL (GB) | 2004-07-29 | — | — | US | disclosed |
| EP-1373218-A1 | IMIDAZOLYL DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS | Ortho McNeil Pharmaceutical, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20020198237-A1 | Heterocyclic compounds | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-12-26 | — | — | US | disclosed |
| WO-2002079168-A1 | IMIDAZOLYL DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143591-A1 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | ABL1, NOS2, FLT3 | HRH3 2308/4885MEN1 980/4885KMT2A 1116/4885 |
| US-20050250948-A1 | Scalable synthesis of imidazole derivatives | ABL1, NOS2, FLT3 | HRH3 2308/4885MEN1 980/4885KMT2A 1116/4885 |
| US-20020198237-A1 | Heterocyclic compounds | HRH2, HRH4, HRH1 | HRH3 4/4885MEN1 2058/4885KMT2A 3733/4885 |
| US-20040147577-A1 | Heterocyclic compounds | HRH2, HRH4, HRH1 | HRH3 4/4885MEN1 2058/4885KMT2A 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.